Brak połączenia z internetem — wyświetlanie zapisanej wersji strony.

Amgen Inc

USUSD
← Do screenera

Amgen Inc (MX:AMGN) — Biotechnology: Biological Products (No Diagnostic Substances). Liczba giełd, na których notowane są akcje spółki: 4. Na tej stronie — cena i wykres, dywidendy, najwięksi akcjonariusze oraz historia liczby akcji.

O firmie

Strona
amgen.com
Relacje inwestorskie
investors.amgen.com/
Sektor
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Siedziba
Thousand Oaks, United States
Prezes
Robert A. Bradway
Pracownicy
17 900
Założona
1980
Notowana od
29.02.2008 (MX:AMGN)
Akcje w obrocie
540.63 mln na 2026-07-30
Free float
539.16 mln
Kapitalizacja rynkowa
226.05 mld USD
Insiderzy
0.23%
Inwestorzy instytucjonalni
85.02%
Branża (SIC)
Biological Products, (No Diagnostic Substances)
Forma prawna
XTIQ
ISIN
US0311621009
LEI
62QBXGPJ34PQ72Z12S66
Stopa wypłaty
60.4%
FCF
10.2 mld USD
52%
Dług
57.3 mld USD
4.3 l. FCF
Staż dywidendowy
15 l.
Zysk, FCF i wypłacone dywidendy — za 12 miesięcy do 30.06.2026 (najnowszy raport spółki).
Opis

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Giełdy i tickery

GiełdaTickerWalutaCenaTyp
US USA StocksAMGN główneUSD407.44 -1.37%akcje zwykłe
HK Hong Kong Stock Exchange4332 dodatkoweHKD—
LSE London Stock Exchange0R0T IOBUSD411.854 +1.17%akcje zwykłe
MX Mexican Stock ExchangeAMGN dodatkoweMXN7 500.0098 +0.00%akcje zwykłe
XETRA XetraAMG dodatkoweEUR367.95 -1.39%akcje zwykłe

Cena z 3 miesięcy

dzień wzrostu dzień spadku dzień ex-dywidendy dzień wypłatyNajedź / dotknij dnia — ceny otwarcia, zamknięcia, najwyższa i najniższa

Dywidendy

Per year, MX:AMGN: 180.7291 MXN (4 wypł.)

Amgen Inc (AMGN) wypłaca dywidendy kwartalnie. Per year (12 months up to and including the latest announced payment): 180.7291 MXN per share (payments: 4). To około 2.41% obecnej ceny akcji. Na podstawie historii wypłat następna data ex-dywidendy spodziewana jest około 20.11.2026. Lata nieprzerwanych dywidend: 15.

Dzień exWypłataKwota%TypTicker
2026-08-21—45.8186 MXN0.6/2.4 %kwartalnieMX:AMGN
2026-05-15—45.8186 MXN0.6/2.4 %kwartalnieMX:AMGN
2026-02-13—45.8186 MXN0.6/2.3 %kwartalnieMX:AMGN
2025-11-21—43.2732 MXN0.6/2.3 %kwartalnieMX:AMGN
2025-08-22—43.2732 MXN0.6/2.3 %kwartalnieMX:AMGN
2025-05-16—43.2732 MXN0.6/2.2 %kwartalnieMX:AMGN
2025-02-14—43.2732 MXN0.6/2.2 %kwartalnieMX:AMGN
2024-11-19—40.9095 MXN0.5/2.2 %kwartalnieMX:AMGN
2024-08-16—40.9095 MXN0.5/2.2 %kwartalnieMX:AMGN
2024-05-16—40.9095 MXN0.5/2.1 %kwartalnieMX:AMGN
2024-02-15—40.9095 MXN0.5/2.1 %kwartalnieMX:AMGN
2023-11-16—38.7277 MXN0.5/2.1 %kwartalnieMX:AMGN
2023-08-17—38.7277 MXN0.5/2.0 %kwartalnieMX:AMGN
2023-05-17—38.7277 MXN0.5/2.0 %kwartalnieMX:AMGN
2023-02-14—38.7277 MXN0.5/1.9 %kwartalnieMX:AMGN
2022-11-16—35.2731 MXN0.5/1.9 %kwartalnieMX:AMGN
2022-08-17—35.2731 MXN0.5/1.8 %kwartalnieMX:AMGN
2022-05-16—35.2731 MXN0.5/1.4 %kwartalnieMX:AMGN
2022-02-14—35.2731 MXN0.5/0.9 %kwartalnieMX:AMGN
2021-11-16—32.0003 MXN0.4/0.4 %kwartalnieMX:AMGN
reklama

Najwięksi akcjonariusze

PosiadaczUdziałAkcjeData raportu
Blackrock Inc.9.13%49.36 mln2026-06-30
Vanguard Capital Managem…6.52%35.25 mln2026-06-30
State Street Corporation5.65%30.56 mln2026-06-30
Capital World Investors5.38%29.08 mln2026-06-30
VANGUARD INDEX FUNDS-Van…3.17%17.13 mln2026-06-30
Invesco Ltd.3.02%16.32 mln2026-06-30
Geode Capital Management…2.9%15.7 mln2026-06-30
Charles Schwab Investmen…2.78%15.03 mln2026-06-30
Vanguard Portfolio Manag…2.75%14.85 mln2026-06-30
VANGUARD INDEX FUNDS-Van…2.59%13.99 mln2026-06-30
Morgan Stanley2.53%13.65 mln2026-06-30
Invesco QQQ Trust, Serie…2.15%11.61 mln2026-08-31
SCHWAB STRATEGIC TRUST-S…1.81%9.79 mln2026-05-31
Income Fund of America1.44%7.76 mln2026-06-30
iShares Trust-iShares Co…1.35%7.28 mln2026-07-31
Wells Fargo & Company1.34%7.24 mln2026-06-30
AMERICAN BALANCED FUND1.31%7.09 mln2026-06-30
Fidelity Concord Street…1.29%6.98 mln2026-07-31
SPDR S&P 500 ETF TRUST-S…1.22%6.6 mln2026-08-31
WASHINGTON MUTUAL INVEST…1.16%6.27 mln2026-06-30
BRADWAY ROBERT A (Chief…≈0.12%657 2992026-05-05
SANTOS ESTEBAN (Officer)≈0.02%84 2792026-05-05
GORDON MURDO (Officer)≈0.01%51 8372026-05-05
GRIFFITH PETER H. (Chief…≈0.01%50 7062026-05-05
REESE DAVID M. (Chief Te…≈0.01%42 8122026-05-05
GRAHAM JONATHAN P (Gener…≈0.01%40 2112026-05-05
BRADNER JAMES E. (Office…≈0.01%30 4622026-05-05
ECKERT ROBERT ANDREW (Di…≈0%26 2512026-05-19
JACKS TYLER (Director)≈0%18 2842026-05-19
KULLMAN ELLEN JAMISON (D…≈0%14 5362026-05-19